- Blood biomarkers present great potential for early detection of cancer
- Device identifies DNA or RNA sequences that differ by one or more nucleotide(s), copy number(s), transcript sequence(s), and/or methylated residue(s)
- Device is sensitive and automated
Biomarkers circulating in the bloodstream present great potential for early detection of cancer. However, DNA sequencing is costly and arduous and quicker assays are not sufficiently sensitive, specific, or inexpensive for widespread clinical use. There is a need for low-cost diagnostics and screens sensitive enough to detect very rare abnormalities in nucleic acid sequences and specific enough to produce no false positives.
A device that sequences and enumerates molecular features in inpatient blood samples has been invented. This device can target and identify sequences that differ by one or more nucleotide(s), copy number(s), transcript sequence(s), and/or methylated residue(s). Sequence variation in both DNA and RNA molecules is detected using several PCR-free molecular reactions, and reaction products are identified by their electrophoretic mobilities. This device eliminates PCR (thereby reducing false positives), digitally counts targets (improving measurement sensitivity), performs a range of molecular assays, and is automated (reducing human error and obviating the need for expensive equipment). This device has been tested for its ability to count cells, extract exosomes, and purify target DNA, among others.
This technology is available for nonexclusive licensing only.
Number:US Patent 10,829,804
Ime: Jackie Quay